Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose - The randomized controlled HOMe aFers study

BMC Medicine

Volumn 18, Issue 1, 2020, Pages

  Emrich, I E ^a   Lizzi, F ^a   Siegel, J D ^a   Seiler Mussler, S ^a,b   Ukena, C ^a   Kaddu Mulindwa, D ^a   D'Amelio, R ^a   Wagenpfeil, S ^a   Brandenburg, V M ^c   Bohm M ^a   Fliser, D ^a   Heine, G H ^a,d  

^a SAARLAND UNIVERSITY   (Germany)

^b VAUBAN Praxis Saarlouis   (Germany)

^c Rhein Maas Klinikum GmbH   (Germany)

^d AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

Ferric carboxymaltose; Ferric derisomaltose; FGF23; Hypophosphatemia; Iron deficiency anemia

Indexed keywords

CALCITRIOL; FERRIC CARBOXYMALTOSE; FIBROBLAST GROWTH FACTOR 23; IRON ISOMALTOSE; PHOSPHORUS; FERRIC ION; IRON; MALTOSE;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; MINERAL METABOLISM; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; URINARY EXCRETION; BLOOD; COMPLICATION; MALE; PROSPECTIVE STUDY;

ADULT; ANEMIA, IRON-DEFICIENCY; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPOPHOSPHATEMIA; IRON; MALE; MALTOSE; PROSPECTIVE STUDIES;

EID: 85087887338     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-020-01643-5     Document Type: Article

References (17)

1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993-2005. Public Health Nutr. 2009;12:444-54. https://doi.org/10.1017/S1368980008002401.
2. Carlsson LE, Hempel S, Greinacher A. Iron deficiency anaemia in young women. Eur J Haematol. 2002;68:341-4. https://doi.org/10.1034/j.1600-0609.2002.00679.x.
3. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121:943-8. https://doi.org/10.1016/j.amjmed.2008.07.012.
4. Estadella J, Villamarín L, Feliu A, Perelló J, Calaf J. Characterization of the population with severe iron deficiency anemia at risk of requiring intravenous iron supplementation. Eur J Obstet Gynecol Reprod Biol. 2018;224:41-4. https://doi.org/10.1016/j.ejogrb.2018.03.005.
5. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719-28. https://doi.org/10.1111/j.1537-2995.2009.02327.x.
6. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3. https://doi.org/10.1172/jci.insight.124486.
7. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia. Curr Opin Nephrol Hypertens. 2017;26:266-75. https://doi.org/10.1097/MNH.0000000000000329.
8. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793-803. https://doi.org/10.1002/jbmr.1923.
9. Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323:432-43. https://doi.org/10.1001/jama.2019.22450.
10. Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M. The medical outcomes study. An application of methods for monitoring the results of medical care. JAMA. 1989;262:925-30. https://doi.org/10.1001/jama.262.7.925.
11. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89-95.
12. Smets EMA, Garssen B, Bonke B, De Haes JCJM. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-25. https://doi.org/10.1016/0022-3999(94)00125-O.
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-63. https://doi.org/10.1016/j.echo.2005.10.005.
14. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011;96:3541-9. https://doi.org/10.1210/jc.2011-1239.
15. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108:E1146-55. https://doi.org/10.1073/pnas.1110905108.
16. Amanzadeh J, Reilly RF. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006;2:136-48. https://doi.org/10.1038/ncpneph0124.
17. Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26:266-75. https://doi.org/10.1097/MNH.0000000000000329.